The humanised anti-EphA2 mAb DS-8895a binds the extracellular juxtamembrane region of EphA2, and inhibits tumour development in EphA2-positive human breast and gastric cancer models, causing antibody-dependent cellular cytotoxicity (ADCC) [122]. Here, EPHA2 is linked to neoplasm.